Radar · Diabetes in United States
Best Diabetes Companies in United States
The 374 best Diabetes companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Intarcia.
By Riya SenguptaFinancials
374companies tracked
$12.6Bdisclosed funding
1unicorns
196have raised
Tracking the best Diabetes companies in the United States by disclosed equity funding and recent momentum, this directory covers 374 companies and $12.6B in total disclosed capital. That's real money. Kriya Therapeutics leads the tracked cohort at $618M raised, with Kailera close behind at $400M and Lexicon Pharmaceuticals at $381M. The global diabetes market sits at roughly $12.0B in 2025, expanding at a 5.92% CAGR, driven by rising prevalence worldwide. So what does earned revenue actually look like here? The sector median net income is $657,619, but the outliers tell a different story: Embecta Corp. pulled $40M in net income, 61 times the median, and vTv Therapeutics posted $24M, 37 times over.
Funding sources skew institutional and mission-driven, with HHS, NIH, and the T1D Fund among the most active backers you'll find across this list. As shown in 2018 research, the clinical complexity of diabetes management continues to shape where capital flows and which therapeutic approaches attract sustained investment. Hot themes right now aren't flashy drug platforms. They're practical: diabetes nutrition therapy, meal planning, blood sugar diet. One unicorn sits in the mix. Coverage is flat, but the funding concentration at the top is anything but.
Ranked: Best Diabetes companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Intarcia 🦄 Provider of osmotic pump for subcutaneous drug delivery | $1.9B | 77 mo ago | 2 | — | — | — | — | — |
| 2 | Sana Biotechnology Developer of engineered cell therapies for treating various human diseases | $821M | 71 mo ago | 328 328 → 258 (-21%) · sector median +53% | Steve Harr Co-Founder & CEO | DrupalApple iCloud MailPHP+26 | 8 signals ▼53% Leadership · IPO · Earnings | 361 patents Engineered cell therapies and gene delivery platforms for regenerative and immunomodulatory medicine. | — |
| 3 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | 5 signals Funding · Capital raise · Leadership | — | — |
| 4 | Carmot Developer of disease-modifying therapies to treat metabolic diseases | $401M | 36 mo ago | 50 | Heather Turner CEO | — | — | — | — |
| 5 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 8 mo ago | — | Ron Renaud Founder & CEO | DrupalApple iCloud MailPHP+27 | 6 signals IPO · Leadership | — | 1 internship |
| 6 | ViaCyte Developer of cell therapy for the treatment of diabetes | $389M | 60 mo ago | 126 | — | — | — | 582 patents Scalable stem cell manufacturing and encapsulated cell delivery devices for regenerative therapies | — |
| 7 | Lexicon Pharmaceuticals Developer of small molecule drugs for diffrent health diseases 76Funding top 20%Patents top 24%Talent top 28%Growth top 30% All 11 signals ▾Fundingtop 20% Patentstop 24% Talenttop 28% Growthtop 30% Techtop 35% Innovationtop 40% Markettop 41% Fin. healthtop 41% Moattop 44% Newstop 45% Globalbottom 44% Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $381M | 4 mo ago | 135 135 → 284 (+110%) · sector median +53% | Ivan Cheung Board of Directors | DrupalApple iCloud MailPHP+31 | 15 signals ▼35% Announcements · Capital raise · Acquisition | 1,211 patents Patents concentrated in chemistry & materials | — |
| 8 | Fractyl Provider of Endoscopic procedure for type - 2 diabetes | $345M | 60 mo ago | 79 79 → 106 (+34%) · sector median +53% | Jay Caplan Co-founder and President | WordPressApple iCloud MailMicrosoft 365+28 | 8 signals ▲300% Leadership · Earnings | — | — |
| 9 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 4 mo ago | — | Sandy Mou CEO | GSAPCloudflare Rocket LoaderSwiper+8 | — | — | — |
| 10 | Beta Bionics Innovating diabetes management with automated bionic pancreas technology | $283M | 19 mo ago | 92 | — | WordPressMySQLPHP+27 | 13 signals ▼19% Earnings · IPO · FDA approval | 208 patents Wearable closed-loop insulin/glucagon patch pump systems and dosing algorithms for diabetes | — |
| 11 | Livongo Provider of smart devices for diabetes management for patients and doctors | $237M | 72 mo ago | 163 | — | SentryApple iCloud MailSalesforce+25 | — | — | — |
| 12 | Bigfoot Biomedical Developer of a closed-loop automated insulin delivery system | $215M | 62 mo ago | 133 | — | HubSpot CMS HubApple iCloud MailGoogle Workspace+23 | — | 631 patents Automated insulin delivery and diabetes management devices and monitoring systems | — |
| 13 | Structure Developer of oral small molecule drugs for chronic diseases | $191M | 46 mo ago | 93 93 → 232 (+149%) · sector median +53% | — | MoodleDrupalApple iCloud Mail+32 | 3 signals ▼77% Earnings · Leadership | — | — |
| 14 | CinRx Pharma Developer of therapeutics targeting various conditions to improve clinical outcomes | $176M | 24 mo ago | 20 | Jonathan Isaacsohn CEO & President | — | — | — | — |
| 15 | Biolinq Provider of a wearable biosensor platform for diabetes monitoring 67Innovation top 13%Funding top 17%Patents top 17%Moat top 26% All 10 signals ▾Innovationtop 13% Fundingtop 17% Patentstop 17% Moattop 26% Talenttop 38% Growthtop 45% Marketbottom 45% Globalbottom 43% Techbottom 39% Newsbottom 18% Innovation: 189 patents (top 11% of patent-holders) · 161 filings since 2022 vs 28 in 2017-21 Funding: Raised $175M across 15 rounds · 15 rounds over 12 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $175M | 15 mo ago | 91 | Jared Tangney Co-Founder | Webflowcore-jsjQuery+11 | — | 189 patents Minimally invasive microneedle-based continuous biosensing for interstitial fluid analytes | — |
| 16 | Xeris Pharmaceuticals Developer of liquid-stable injectables for the delivery of drugs | $155M | 53 mo ago | 294 294 → 506 (+72%) · sector median +53% | Steve Prestrelski Co-Founder & CSO | DrupalApple iCloud MailPHP+32 | 3 signals ▼25% Earnings · Leadership | 249 patents Stable drug formulations, especially levothyroxine, using aprotic polar solvents | 1 internship · 1 award |
| 17 | OrsoBio Developer of therapeutics for multiple metabolic diseases | $152M | 15 mo ago | 10 | — | WordPressMySQLPHP+15 | — | 45 patents Small-molecule LXR modulators and ACMSD inhibitors for dyslipidemia and metabolic disease therapy | — |
| 18 | Endogenex Developer of medical devices for the treatment of Type 2 diabetes 37Funding top 18%Innovation top 39%Moat top 39%Patents top 41% All 9 signals ▾Fundingtop 18% Innovationtop 39% Moattop 39% Patentstop 41% Talentbottom 49% Globalbottom 37% Techbottom 35% Marketbottom 31% Newsbottom 20% Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $140M | 2 mo ago | 15 15 → 27 (+80%) · sector median +53% | Michael Brenzel Co-Founder & CTO | WordPress Block EditorWordPressMySQL+16 | — | 25 patents Pulsed electric field electroporation devices for tissue ablation, especially gastrointestinal applications. | 1 launch |
| 19 | Cour Pharma Developer of biotech nano-particles for immune diseases | $135M | 28 mo ago | 31 | John Puisis Founder | — | — | — | — |
| 20 | Cellino Developer of autologous cell therapies | $125M | 20 mo ago | 43 43 → 107 (+149%) · sector median +53% | Matthias Wagner Co-Founder & CTO | SanityNode.jsThree.js+11 | — | — | 1 award |
| 21 | Viome Life Sciences Provider of tests to prevent, treat, and cure chronic diseases, and cancer | $92M | 21 mo ago | 136 | Momchilo Vuyisich Co-Founder & Chief Science Officer | Node.jsTailwind CSSReact+14 | — | — | — |
| 22 | Trice Medical Minimally invasive solutions for orthopedic and podiatric procedures, improving patient outcomes | $85M | 34 mo ago | 72 72 → 52 (-28%) · sector median +53% | — | WordPressMySQLMariaDB+34 | — | — | — |
| 23 | Podimetrics Provider of diabetic foot ulcer monitoring device for patients and doctors | $75M | 42 mo ago | 10 | David Linders Co-founder and CTO | WordPressApple iCloud MailGoogle Workspace+26 | — | 73 patents Remote monitoring devices for heart failure and diabetic foot complications | — |
| 24 | Know Labs Developer of non-invasive technology for identifying and measuring molecules | $63M | 42 mo ago | 11 | Ron Erickson Founder & Chairman | WixSentryBootstrap+12 | — | 217 patents Non‑invasive RF/microwave sensing for biomedical SpO₂ and structural health monitoring | — |
| 25 | Diasome Developer of therapies for the treatment of diabetes and other metabolic conditions | $60M | 22 mo ago | 7 | W Blair Geho Founder & Director | — | — | — | 1 launch |
| 26 | Aerami Developer of therapeutics to treat cardiopulmonary diseases | $58M | 31 mo ago | 17 | — | — | — | — | — |
| 27 | Levels Provider of wearable device for personalized insights into metabolic health 60Funding top 26%Talent top 28%Tech top 31%Moat top 31% All 10 signals ▾Fundingtop 26% Talenttop 28% Techtop 31% Moattop 31% Customerstop 32% Globaltop 46% Growthbottom 48% Productbottom 48% Marketbottom 43% Newsbottom 18% Funding: Raised $57.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 60/100 | $57M | 22 mo ago | 35 | Josh Clemente Co-Founder | Cart FunctionalitySentryUnbounce+25 | — | — | — |
| 28 | VTV Therapeutics Developer of small molecules for diabetes, muscle weakness and inflammatory diseases | $49M | 27 mo ago | 22 | Paul Sekhri Chairman | DrupalPHPAmazon Web Services+21 | 3 signals ▼75% Earnings | 321 patents Small-molecule therapeutics for metabolic, neurodegenerative, and bone disease targets | — |
| 29 | Veralox Therapeutics Developer of small molecules for treating thrombosis and diabetes pathologies | $47M | 35 mo ago | 6 | Matthew Boxer Co-Founder and COO | — | — | — | — |
| 30 | GlucoTrack Provider of blood glucose monitor for continuous glucose monitoring | $45M | 22 mo ago | 3 | David Malka Co-Founder | WordPress Block EditorWordPressMySQL+28 | 10 signals ▲233% Capital raise · Funding · Announcements | 10 patents Implantable low‑power continuous glucose sensors with rapid response and spinal‑cord stimulation integration | 2 launchs · 1 partnership |
| 31 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 30 mo ago | 4 | — | — | — | — | — |
| 32 | Signos Provider of a wearable device for blood glucose pattern monitoring 42Tech top 20%Funding top 25%Moat top 39%Customers top 44% All 10 signals ▾Techtop 20% Fundingtop 25% Moattop 39% Customerstop 44% Producttop 46% Talentbottom 49% Marketbottom 40% Globalbottom 36% Growthbottom 31% Newsbottom 22% Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $37M | 0 mo ago | 30 | Sharam Fouladgar-Mercer Co-Founder & CEO | Webflow EcommerceWebflowGSAP+27 | — | — | — |
| 33 | Siren Provides smart socks for preventing diabetic foot ulcers 42Talent top 28%Funding top 29%Growth top 35%Product top 46% All 7 signals ▾Talenttop 28% Fundingtop 29% Growthtop 35% Producttop 46% Techbottom 45% Globalbottom 39% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $30.9M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $31M | 17 mo ago | 22 | Henk Scholten Co-Founder & COO | WebflowMicrosoft AdvertisingPriority Hints+14 | — | — | — |
| 34 | Movano Health Developer of radio frequency-enabled health monitoring devices and wearable technology | $30M | 26 mo ago | 27 | John Mastrototaro CEO | WordPressMySQLPHP+16 | — | — | — |
| 35 | Modular Medical Developer of insulin pump designed for simplified diabetes management and care | $20M | 14 mo ago | — | Paul Diperna Founder | WebflowMicrosoft 365jQuery+6 | — | — | — |
| 36 | Paulex Bio Developer of therapeutics for diabetes treatment | $19M | 6 mo ago | — | Miguel Sanjuan CEO & Founder | — | — | — | — |
| 37 | Surf Bio Developer of therapeutics for the treatment of multiple diseases | $16M | 25 mo ago | 4 | Jennifer Schneider Md Founder | — | — | — | — |
| 38 | Laxmi Therapeutic Devices Develper of a wearable diagnostic device for continuous glucose monitoring | $14M | 22 mo ago | 38 38 → 30 (-21%) · sector median +53% | Bill Antwerp Co-Founder | — | — | — | — |
| 39 | AltrixBio Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases | $13M | 9 mo ago | 5 | — | — | — | 2 patents Mucoadhesive drug delivery formulations for targeted mucosal administration | — |
| 40 | IBS Developer of fingerprint drug testing and sweat drug monitoring solutions 42Innovation top 23%Product top 35%Funding top 42%News top 42% All 10 signals ▾Innovationtop 23% Producttop 35% Fundingtop 42% Newstop 42% Techtop 45% Talentbottom 49% Growthbottom 47% Fin. healthbottom 34% Marketbottom 33% Globalbottom 30% Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware Product: 0 product launch events in 12 mo, 4 the year before · Company stage: Public rank vs industry peers · Fliar Intelligence Index 42/100 | $10M | 5 mo ago | 26 | Harry Simeonidis President and CEO IBS Inc | WordPressMySQLPHP+28 | 24 signals Earnings · Announcements · Funding | — | — |
| 41 | Vivani Developer of a drug delivery medical device for diabetes | $8M | 14 mo ago | 37 37 → 36 (-3%) · sector median +53% | Adam Mendelsohn Co-Founder & CEO | WordPressMySQLPHP+25 | 15 signals ▲200% Acquisition · Funding · Earnings | — | 2 launchs |
| 42 | Renova Therapeutics Developer of gene therapies for congestive heart failure and type 2 diabetes | $8M | 22 mo ago | 7 | Jack Reich Chief Executive Officer | WordPressMySQLPHP+17 | — | — | — |
| 43 | Eden Medical Developer of medical device for the treatment of wounds | $8M | 21 mo ago | — | Jeffrey Schoess President and CEO | — | — | — | — |
| 44 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | — | Google MapsBootstrapNginx+6 | — | — | 1 job opening |
| 45 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | Andy Wardle Co-Founder & Advisor | — | — | — | — |
| 46 | IMS Provider of a wearable smart sensor for glucose monitoring | $5M | 10 mo ago | 5 | Muhammad U Rahman Founder | — | — | 72 patents Vehicle telematics and driver behavior analytics, including OBD, smartphone integration, and traffic alerts | — |
| 47 | SFC Fluidics Developer of microfluidic technology for diabetes care and chronic pain 35Talent top 28%Product top 30%Moat top 32%Funding top 38% All 8 signals ▾Talenttop 28% Producttop 30% Moattop 32% Fundingtop 38% Innovationtop 43% Patentstop 43% Globalbottom 35% Marketbottom 25% Talent: Analyst team rating 4/5 Product: 5 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 35/100 | $4M | 8 mo ago | 11 | — | — | — | 37 patents Microfluidic latching valves and wearable drug infusion system technologies | — |
| 48 | AmideBio Peptide therapeutics innovator targeting metabolic diseases with custom synthesis services | $3M | 21 mo ago | 8 | — | — | — | 49 patents Glucose‑responsive insulin and glucagon peptide therapeutics for diabetes management | — |
| 49 | Pacific Diabetes Technologies Innovative diabetes management solutions through a single, integrated device | $2M | 8 mo ago | 15 | Robert S. Cargill CEO & President | — | — | 40 patents Integrated closed-loop insulin delivery and continuous glucose monitoring via trocarless biosensor cannula. | — |
| 50 | Metanoia Bio Provider of platform technology to prevent diabetes | $1M | 3 mo ago | 5 | Jake Mendelsohn Co-Founder | — | — | — | — |
Top 12 Diabetes companies in United States
#1
Public · The Woodlands, Texas · founded 1995 · 135 employees$381.3Mraised▾
Public · The Woodlands, Texas · founded 1995 · 135 employees
Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Fliar Intelligence Index™ 76how this company ranks against its industry peers
Funding
top 20%Patents
top 24%Talent
top 28%Growth
top 30%Tech
top 35%Innovation
top 40%Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) · Last round Post IPO (Feb 2026)
Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 · Latest publication 2026
Talent: Analyst team rating 5/5 · 2 named leaders on record
Audience (LinkedIn): 24k LinkedIn followers — 8.5% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$55.7M
- Aug 2022Post IPO$42.9M
- Mar 2017Post IPO$10.5M
- Dec 2014Post IPO$4.7M
Founders & team
Investors
Bay City Capital, New Enterprise Associates, Military Health, BCM Technologies, Genechem
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApple Icloud MailCore-JsDocusign
#2
Series C · Plymouth, Minnesota · founded 2017 · 15 employees$140.4Mraised▾
Series C · Plymouth, Minnesota · founded 2017 · 15 employees
Developer of medical devices for the treatment of Type 2 diabetes. The company has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with Type 2 diabetes.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 18%Innovation
top 39%Moat
top 39%Patents
top 41%Talent
bottom 49%Global
bottom 37%Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series C (Mar 2026)
Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 · Deep-tech classification: Tech Hardware
Moat: Editorial + unicorn rating 3/10 · IP moat: 25 patents · Soonicorn
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: transformative healthcare
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Series C$50M
- Jun 2024Series C$88M
- Oct 2023Series B$18.3M
- Feb 2023Series A$9.2M
Founders & team
Investors
FDA, Hatteras Venture Partners, Lumira Ventures, Orlando Health, Intuitive, Longitude Capital
#3
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Series D · Berkeley Heights, New Jersey · founded 2019
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Jan 2026Series D$287M
Founders & team
Investors
SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCloudflare Rocket LoaderGoogle Font ApiHstsHttp/3
#4
Series B · San Francisco, California · founded 2020 · 30 employees$37Mraised▾
Series B · San Francisco, California · founded 2020 · 30 employees
Provider of a wearable device for blood glucose pattern monitoring. The company has developed an app-based platform that recommends meals and exercises for users based on the glucose pattern detected through the connected device. The app provides real-time glucose monitoring and glucose spike levels for different foods. Based on this, personalized fitness and nutrition plan can be developed.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Tech
top 20%Funding
top 25%Moat
top 39%Customers
top 44%Product
top 46%Talent
bottom 49%Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Devops: Envoy
Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 9k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Oct 2023Series B$20M
- Nov 2021Series A$13M
- Jan 2021Seed$4M
Founders & team
Investors
Cheyenne Ventures, Google Ventures, Dexcom Ventures, Samsung NEXT, Courtside Ventures, 1984 Ventures
Tech stack
AddshoppersAmazon CloudfrontAmazon Web ServicesCloudflareCloudflare Bot ManagementCore-Js
#5
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Public · Waltham, Massachusetts · founded 2024
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 12%Growth
top 20%News
top 22%Moat
top 31%Tech
top 40%Talent
bottom 41%Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series B (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 6 tracked, 2 types) · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO, Leadership
Audience (LinkedIn): 17k LinkedIn followers — 6.0% of this cohort's audience
Funding rounds
- Oct 2025Series B$600M
- Oct 2024Series A$400M
Founders & team
Investors
Atlas Venture, Bain Capital Life Sciences, RTW Investments, Bain Capital Private Equity, Adage Capital Management, CPP Investments
Tech stack
AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#6
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#7
Series A · Needham, Massachusetts · founded 2020 · 5 employees$5.6Mraised▾
Series A · Needham, Massachusetts · founded 2020 · 5 employees
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
Fliar Intelligence Index™ 7how this company ranks against its industry peers
Funding
top 37%Moat
top 48%Global
bottom 36%Tech
bottom 22%Market
bottom 20%Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 7 hiring posts in 12 mo (public) · momentum -2 · hiring: Research Associate, Scientist/Senior Scientist, Molecular Biology
Activity (LinkedIn): 1 partnerships (incl. Lilly) announced in 12 mo
Funding rounds
- May 2026Series A$1.5M
- Sep 2024Seed—
- Aug 2023Grant (prize money)$275K
- Aug 2022Seed$2.3M
Investors
LifeSpan Vision Ventures, Sherwood Ventures, Longevitytech.fund, Primo Medical Group, Angel Star Ventures, APIS Health Angels
#8
Series C · San Diego, California · founded 2012 · 91 employees$175.1Mraised▾
Series C · San Diego, California · founded 2012 · 91 employees
Provider of a wearable biosensor platform for diabetes monitoring. It offers a wireless microsensor that enables users to understand their metabolism and blood glucose levels in real-time.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 13%Funding
top 17%Patents
top 17%Moat
top 26%Talent
top 38%Growth
top 45%Innovation: 189 patents (top 11% of patent-holders) · 161 filings since 2022 vs 28 in 2017-21 · Deep-tech classification: Tech Hardware
Funding: Raised $175M across 15 rounds · 15 rounds over 12 yrs (1.2/yr) · Last round Series C (Mar 2025)
Patents: 189 patents matched (strict assignee match) · 161 filings since 2022 vs 28 in 2017-21 · Latest publication 2026
Funding rounds
- Mar 2025Series C$100M
- Dec 2023Series B$59.1M
- Nov 2021Series B$100M
- Sep 2021Grant (prize money)$1.9M
Founders & team
Investors
M Ventures, Hikma Ventures, Three Leaf Ventures, LifeSci Venture Partners, GSVP, Alpha Wave Global
Tech stack
Google AnalyticsGreenhouseJqueryJsdelivrLottiefilesOpen Graph
#9
Public · Boston, Massachusetts · founded 2015 · 92 employees$282.9Mraised▾
Public · Boston, Massachusetts · founded 2015 · 92 employees
Innovating diabetes management with automated bionic pancreas technology. The company pioneers the development of the iLet Bionic Pancreas, an insulin delivery system designed to simplify diabetes management. This innovative technology reduces the burden of decision-making for individuals with diabetes by automating insulin dosing based on continuous glucose monitoring data. The system learns individual insulin needs, eliminating the need for manual carb counting and corrections. The company is dedicated to improving the lives of people with diabetes through user-friendly technological solutions. They focus on creating a supportive community and providing resources for both patients and healthcare professionals. Their commitment extends to ongoing research, clinical trials, and continuous product development to enhance the effectiveness and accessibility of their bionic pancreas system. The company is focused on social impact by making diabetes management easier.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 20k LinkedIn followers — 7.1% of this cohort's audience
Funding rounds
- Nov 2024Series E$60M
- Aug 2023Series D$100M
- Feb 2022Series C$57M
- Sep 2019Grant (prize money)$2M
Investors
Sands Capital, Omega Funds, Marshall Wace, Soleus Capital, Eventide Asset Management, Farallon Capital Management
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Cloudfront
#10
Series B · Palo Alto, California · founded 2021 · 10 employees$151.6Mraised▾
Series B · Palo Alto, California · founded 2021 · 10 employees
Developer of therapeutics for multiple metabolic diseases. It offer drug cangidates that target central pathways of energy metabolism which include ACC2 inhibitor TLC-3595 for type-2 diabetes, LXR inverse agonist TLC-2716 for Severe Dyslipidemias, Mitochondrial protonophore TLC-6740, and TLC-1235 for Lipodystrophies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Feb 2025Series B$1.7M
- Feb 2025Grant (prize money)$2.3M
- Aug 2024Series B$67M
- Oct 2023Series A$84.6M
Investors
Longitude Capital, Enavate Sciences, Samsara BioCapital, NuevaBio, Lilly, Ascenta Capital
#11
Series B · San Diego, California · founded 2023$18.5Mraised▾
Series B · San Diego, California · founded 2023
Developer of therapeutics for diabetes treatment. It offers regeneration therapies for the treatment and prevention of Type-1 and Type-2 Diabetes.
Funding rounds
- Nov 2025Series B$18.5M
Founders & team
#12
Public · New York City, New York · founded 2016 · 26 employees$10Mraised▾
Public · New York City, New York · founded 2016 · 26 employees
Developer of fingerprint drug testing and sweat drug monitoring solutions. The company provides a system that detects drugs via fingertip sweat. It also offers a wearable patch that detects drug use through sweat over several days. The patch is designed for longer-term monitoring purposes.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Innovation
top 23%Product
top 35%Funding
top 42%News
top 42%Tech
top 45%Talent
bottom 49%Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware
Product: 0 product launch events in 12 mo, 4 the year before · Company stage: Public
Funding: Raised $10.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Post IPO (Dec 2025)
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Dec 2025Post IPO$10M
- Mar 2024Post IPO—
Founders & team
Tech stack
CloudflareCloudflare Bot ManagementCookieyesCore-JsElementorFacebook Pixel
Funding & investor landscape
$12.6Btotal disclosed funding
207companies funded
1,004disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Ivan Cheung
Board of Directors · Lexicon Pharmaceuticals
Ray Debbane
Chairman of Board · Lexicon Pharmaceuticals
Michael Brenzel
Co-Founder & CTO · Endogenex
Sandy Mou
CEO · CORXEL
Sharam Fouladgar-Mercer
Co-Founder & CEO · Signos
Ron Renaud
Founder & CEO · Kailera
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Jared Tangney
Co-Founder · Biolinq
Richard Yang
CEO · Biolinq
Miguel Sanjuan
CEO & Founder · Paulex Bio
Francisco Leon
Co-Founder · Paulex Bio
Prism market signals · United States · country-scoped Prism corpus, 11,125,692 docs
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Diabetes companies are there in United States?
Radar tracks 374 indexable Diabetes companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Diabetes companies in United States?
The Diabetes companies in United States on this list have raised a combined $12.6B in disclosed equity funding across 207 funded companies.
Which is the highest-funded Diabetes company in United States?
Intarcia is the highest-funded Diabetes company in United States, with $1.9B in disclosed equity funding.
How many Diabetes companies in United States are funded?
207 of the 374 Diabetes companies in United States on this list have disclosed at least one equity funding round.
How many Diabetes unicorns are there in United States?
1 Diabetes company in United States on this list is valued at $1B or more.
Who are the top investors in United States Diabetes companies?
The most active investors in United States Diabetes companies on this list include HHS, NIH, T1D Fund, National Science Foundation, BioBrit.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.